Wednesday, October 6
Subject to change
- Sara Jane Demy, Founder & CEO, Demy-Colton
Morning Plenary: Psychedelics and Virtual Reality: Entering a New era of Experiential Medicine
Our lives on this planet have improved in so many amazing ways – notably in terms of our health, longevity, literacy, and resources. Despite such significant advances, clear signs are present that our species is struggling in a fundamental way: the strength of our minds. Dr. Gazzaley believes that we are experiencing an emerging, global cognition crisis, presenting itself as a growing lack of high-level attention, emotional regulation, decision making, creativity, empathy, compassion and wisdom.
While it has become clear that modern information technology has aggravated this crisis, there is also an untapped potential for it to offer us a solution. Dr. Gazzaley will describe an approach he has advanced over the last decade to create and validate a new era of experiential medicine – one delivered via personalized, adaptive, interactive experiences designed to achieve meaningful and sustainable cognitive enhancement. He will take you on a deep dive into his efforts to integrate these custom-designed, closed-loop video games with innovations in virtual reality, motion capture, physiological recordings, brain-computer interfaces, non-invasive brain stimulation and artificial intelligence. Addressing this grand challenge of enhancing cognition requires a creative future-thinking approach, but has the potential to improve the quality of our lives and manage the many other crises that humans face.
- Leslie Gautam, Executive Director, Torreya
- Adam Gazzaley, MD, PhD, David Dolby Distinguished Professor of Neurology, Physiology & Psychiatry, UC San Francisco; Founder & Executive Director, Neuroscape
Dialogue 5 – Manufacturing: The Next Big COVID Problem or Worse?
COVID-19 has exposed critical vulnerabilities in medical supply chains, and today's manufacturing can't keep up with scientific innovation, medical discovery, and the need to rapidly produce and distribute critically important drugs at scale. Learn from speakers on this panel to see how manufacturing companies are committed to tackling these huge problems with a whole new business model. Hear about advancements in biopharmaceutical manufacturing and how new technology is broadening access to novel therapies and vaccines while protecting supply chains against disruption.
- Steve Brozak, Managing Partner & President, WBB Securities
- Chandresh Harjivan, COO, SaponiQx
- Tyler Martin, MD, CEO, Adjuvance
- Molly McGlaughlin, Former COO, Vigene Biosciences
- Kurt Nielsen, PhD, President & CEO, Pii
Salon 5 – Modern Medicine: Combining Digital Technology with Psychedelic Therapy
Psychedelic therapies are showing tremendous promise in clinical trials and are one of the biggest breakthroughs in psychiatry in the last few decades. Researchers are now combining these therapies with digital technologies that could transform the way in which we care for patients with mental health challenges, for example, by predicting mental health states or measuring the impact of treatment. Technology, AI, and big data have the potential to enhance care and improve outcomes, but patients must be confident their data are carefully handled and only used for their benefit. This panel will discuss what needs to be done to get this right.
- Walter Greenleaf, PhD, Distinguished Visiting Scholar, Stanford University’s MediaX Program
- Isaac Galatzer-Levy, PhD, Adjunct Assistant Professor, Department of Psychiatry, NYU School of Medicine
- Lara Gregorio, Co-Founder & President, Humanest
- Lucia Huang, Co-Founder & CEO, Osmind
- Greg Ryslik, Senior Vice-President, Data Science, Machine Learning, & Digital Health Research, COMPASS Pathways
Spotlight Sessions – Humans vs Machines Round 2
This is Round Two of a first-of-its kind competition to determine the power of clinical trial prediction. A team of Human KOLs or an Artificial Intelligence driven program. The teams will provide a readout of the first round of this competition which took place in June and make predictions on the next group of assets. Join us to learn if humans or machines are better at predicting results.
- Ly Nguyen-Jatkoe, PhD, Executive Director, Pharma Custom Intelligence, Informa
- Mark Gordon, Founder & CEO, Diviner
- Matthias Kopf, PhD, Head of Product Management, Molecular Health GmbH
- Daniel Mytelka, PhD, Head of Methodology, Diviner
- Friedrich von Bohlen, PhD, Co-Founder & CEO, Molecular Health GmbH
Dialogue 6 – Venture Capital Trends in Digital Health
Leading VC investors will discuss how advances in AI and machine learning, nanotechnology, optics, quantum physics, and advances in engineering are transforming the life sciences industry. Learn how technology-driven convergence will both disrupt and benefit pharma and biotech. These VC partners will discuss why convergence is a critical component for innovation. Panelists will also discuss case studies and startups showcasing “convergence in action,” from digital health to biotech.
- Kimberly Ha, CEO & Founder, KKH Advisors
- Betsabeh Madani Hermann, Investor and Executive, Healthcare and Lifesciences
- Chihiro Hosoya, Head of Venture Management & Business Development, Astellas Rx+ Business Accelerator LLC
- Nina Kjellson, General Partner, Canaan Partners
- Shruti Van Dyke Gandhi, General Partner and Founding Engineer, Array Ventures
Salon 6 – Next Wave Diagnostics: AI and Health Innovations Accelerate Dx
You can’t treat what you don’t understand. And the COVID pandemic showed us all too clearly that there’s value in a definitive diagnosis. Early diagnoses can curtail disease, save money, and save lives. Traditional diagnostics can be complex and time consuming, with multiple referrals and specialists involved. Often, they are expensive or highly invasive. There is a better way.
A new wave of diagnostic approaches are providing better, faster and cheaper insights and allowing for earlier interventions, treatments and action. Whether these are companion diagnostics for next gen drugs, direct to consumer tests or IoMT devices, this next wave of diagnostics driven by tech and AI, are driving big business and better health outcomes.
- Beth Rogozinski, CEO, Oncoustics
- Scott D. Danzis, Partner, Covington & Burling LLP
- Seth Rainford, President & COO, Digital Diagnostics
- Andrew Ritter, CEO, Docbot, Inc.
- Komathi Stem, COO, Glooko
- David Suendermann-Oeft, PhD, Founder & CEO, Modality.AI
Lunch & Networking
Dialogue 7 – Innovations & Breakthroughs: How will we Pay for It?
As anticipated, the Biden Administration introduced a plan to lower the cost of prescription drugs, a long-standing, hot-button issue. Patients who cannot afford their medicines are angry and have been for years. Clearly, maintaining the status quo is not the answer. But is the Biden proposal the right formula? The industry and the investors who support them think it is not and as noted in a recent industry letter to elected leadership, “some lawmakers have misdiagnosed the problem.” What is the solution to this intractable problem?
- Jennifer Hawks Bland, CEO, NewYorkBio
- Jeremy Levin, MD, PhD, Chairman & CEO, Ovid Therapeutics Inc.
- Tim Opler, PhD, Partner & Co-Founder, Torreya
- Art Pappas, Managing Partner, Pappas Capital
- Peter Rubin, Executive Director, No Patient Left Behind
- Barbara Ryan, CEO, Barbara Ryan Advisors
Salon 7 – The New Wave of Disease-Modifying Digital Therapeutics
A new class of digital therapeutics are advancing beyond prior digital products’ focus on tracking adherence or simply digitizing existing mechanisms of action. This revolutionary class of digital treatments engage targets of disease to positively alter the course of treatment. Learn how next-generation digital therapeutics are demonstrating how they improve outcomes, supported by clinical and real-world evidence, including high impact, unmet needs in areas such as Alzheimer’s, autoimmunity, stroke recovery, and cognition.
- Melinda Decker – Chief Commercial Officer – Mymee
- Paolo Cassano, MD, PhD, Assistant Professor in Psychiatry, Massachusetts General Hospital / Harvard University
- Brian Harris, CEO & Co-Founder, MedRhythms
- Nigel Howard, Partner, Covington & Burling LLP
- Eddie Martucci, CEO, Akili Interactive Labs
- Marie Thibault, Managing Director, Medical Technology & Digital Health Equity Research, BTIG
Dialogue 8 – Decentralized Clinical Trials: An Evolving New Model is Changing the Landscape
Panelists will discuss how hybrid and decentralized trials have altered traditional clinical trials. As a result of the COVID-19 pandemic, a new landscape has emerged that sponsors, sites, and patients must navigate as a result. The panelists will also highlight the challenges and opportunities with transitioning to a hybrid or decentralized trial strategy and what they would recommend for those planning to do the same.
- Zeil Rosenberg, MD, Executive Director, PPD Biotech
- Sam Eells, Co-Founder & Chief Design Officer, Lightship
- Darcy Forman, Chief Delivery Officer, Science 37
- Kimberly Tableman, Chief Clinical Development Officer, Castor
Salon 8 – The Leading Edge of Healthcare: New Targets, Novel Therapeutic Approaches, Cutting-Edge Technologies
- Padma Thiruvengadam, Former CHRO, Takeda Pharmaceuticals
- Jacob Becraft, PhD, Co-Founder & CEO, Strand Therapeutics
- Aldo Carrasco, CEO, InterVenn
- Alex Nichols, PhD, President & CEO, Mythic Therapeutics
- Daniel Oliver, Co-Founder & CEO, Rejuvenate Bio
Spotlight Sessions – Cell & Gene Therapy
Power Networking Hour
A Fireside Chat – A Discussion on Changing the Trajectory of Health for Humanity, Eliminating Disease and Pursuing Innovation Wherever It Originates
- Christina Jenkins, MD, Venture Partner, Phoenix Venture Partners (PVP)
- William N. Hait, MD, PhD, Global Head, Johnson & Johnson External Innovation, J&J